Needham Initiates Coverage On Artiva Biotherapeutics with Buy Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy rating and a price target of $23.

August 13, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has initiated coverage on Artiva Biotherapeutics with a Buy rating and a price target of $23.
The initiation of coverage with a Buy rating and a specific price target of $23 by a reputable analyst is likely to positively impact the stock price of Artiva Biotherapeutics in the short term. This is because such ratings often attract investor interest and can lead to increased buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100